6144 related articles for article (PubMed ID: 3502453)
1. Effect of cyclophosphamide on the immunogenicity of monoclonal antimelanoma antibody-ricin A chain immunotoxin in rats.
Harkonen S; Mischak R; Lopez H; Stoudemire J
Cancer Drug Deliv; 1987; 4(3):151-7. PubMed ID: 3502453
[TBL] [Abstract][Full Text] [Related]
2. The effects of cyclophosphamide on the toxicity and immunogenicity of ricin A chain immunotoxin in rats.
Stoudemire JB; Mischak R; Foxall C; Harkonen WS; Del Rio M; Spitler LE
Mol Biother; 1990 Sep; 2(3):179-84. PubMed ID: 2222902
[TBL] [Abstract][Full Text] [Related]
3. Toxicity and immunogenicity of monoclonal antimelanoma antibody-ricin A chain immunotoxin in rats.
Harkonen S; Stoudemire J; Mischak R; Spitler LE; Lopez H; Scannon P
Cancer Res; 1987 Mar; 47(5):1377-82. PubMed ID: 3493064
[TBL] [Abstract][Full Text] [Related]
4. Antimelanoma monoclonal antibody-ricin A chain immunoconjugate (XMMME-001-RTA) plus cyclophosphamide in the treatment of metastatic malignant melanoma: results of a phase II trial.
Oratz R; Speyer JL; Wernz JC; Hochster H; Meyers M; Mischak R; Spitler LE
J Biol Response Mod; 1990 Aug; 9(4):345-54. PubMed ID: 2395000
[TBL] [Abstract][Full Text] [Related]
5. Human antibody responses to components of the monoclonal antimelanoma antibody ricin A chain immunotoxin XomaZyme-MEL.
Mischak RP; Foxall C; Rosendorf LL; Knebel K; Scannon PJ; Spitler LE
Mol Biother; 1990 Jun; 2(2):104-9. PubMed ID: 2363853
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of monoclonal antibody-ricin A chain immunotoxin XomaZyme-791 in patients with metastatic colon cancer.
Byers VS; Rodvien R; Grant K; Durrant LG; Hudson KH; Baldwin RW; Scannon PJ
Cancer Res; 1989 Nov; 49(21):6153-60. PubMed ID: 2790828
[TBL] [Abstract][Full Text] [Related]
7. Suppression of antibody responses to ricin A chain (RTA) by monoclonal anti-RTA antibodies.
Byers VS; Austin EB; Clegg JA; Denton G; Gunn B; Hooi D; Hudecz F; Price MR; Baldwin RW
J Clin Immunol; 1993 Nov; 13(6):406-14. PubMed ID: 7507127
[TBL] [Abstract][Full Text] [Related]
8. Long-term reduction of vasopressin excretion induced by the central injection of an immunoconjugate (antibody to vasopressin linked to ricin A chain).
Burlet A; Chapleur-Chateau M; Haumont-Pellegri B; Jansen F; Menzaghi F; Fernette B; Nicolas JP; Burlet C
Neuroscience; 1992 Oct; 50(4):965-73. PubMed ID: 1448207
[TBL] [Abstract][Full Text] [Related]
9. Humoral immune response to a ricin A chain immunotoxin in patients with metastatic melanoma.
Hertler AA; Spitler LE; Frankel AE
Cancer Drug Deliv; 1987; 4(4):245-53. PubMed ID: 3502618
[TBL] [Abstract][Full Text] [Related]
10. Humoral immune responses to XMMCO-791-RTA immunotoxin in colorectal cancer patients.
Durrant LG; Byers VS; Scannon PJ; Rodvien R; Grant K; Robins RA; Marksman RA; Baldwin RW
Clin Exp Immunol; 1989 Feb; 75(2):258-64. PubMed ID: 2784738
[TBL] [Abstract][Full Text] [Related]
11. Comparative biochemical, cytotoxic and pharmacokinetic properties of immunotoxins made with native ricin A chain, ricin A1 chain and recombinant ricin A chain.
Wawrzynczak EJ; Cumber AJ; Henry RV; Parnell GD
Int J Cancer; 1991 Jan; 47(1):130-5. PubMed ID: 1985869
[TBL] [Abstract][Full Text] [Related]
12. Prevention of growth of leukemia cells in mice by monoclonal antibodies directed against Thy 1.1 antigen disulfide linked to two ribosomal inhibitors:pokeweed antiviral protein or ricin A chain.
Ramakrishnan S; Houston LL
Cancer Res; 1984 Apr; 44(4):1398-404. PubMed ID: 6142765
[TBL] [Abstract][Full Text] [Related]
13. Antibody formation against the cytotoxic proteins abrin and ricin in humans and mice.
Godal A; Fodstad O; Pihl A
Int J Cancer; 1983 Oct; 32(4):515-21. PubMed ID: 6618711
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II study of murine monoclonal antibody-ricin A chain (XOMAZYME-Mel) immunoconjugate plus cyclosporine A in patients with metastatic melanoma.
Selvaggi K; Saria EA; Schwartz R; Vlock DR; Ackerman S; Wedel N; Kirkwood JM; Jones H; Ernstoff MS
J Immunother Emphasis Tumor Immunol; 1993 Apr; 13(3):201-7. PubMed ID: 8471594
[TBL] [Abstract][Full Text] [Related]
15. Single-dose murine monoclonal antibody ricin A chain immunotoxin in the treatment of metastatic melanoma: a phase I trial.
Gonzalez R; Salem P; Bunn PA; Zukiwski AA; Lamb R; Benjamin RS; Spitler L; Wedel N; Robinson WA
Mol Biother; 1991 Dec; 3(4):192-6. PubMed ID: 1768370
[TBL] [Abstract][Full Text] [Related]
16. Study of the plasma clearance of antibody--ricin-A-chain immunotoxins. Evidence for specific recognition sites on the A chain that mediate rapid clearance of the immunotoxin.
Bourrie BJ; Casellas P; Blythman HE; Jansen FK
Eur J Biochem; 1986 Feb; 155(1):1-10. PubMed ID: 3948873
[TBL] [Abstract][Full Text] [Related]
17. Potent and specific killing of human malignant brain tumor cells by an anti-transferrin receptor antibody-ricin immunotoxin.
Zovickian J; Johnson VG; Youle RJ
J Neurosurg; 1987 Jun; 66(6):850-61. PubMed ID: 3033171
[TBL] [Abstract][Full Text] [Related]
18. [Cytotoxicity of a conjugate of ricin A-chain and monoclonal anti-allotypic antibody].
Rachmanova VA; Tonevitskiĭ AG; Cherapakhin VV; Bobreneva RA
Biull Eksp Biol Med; 1988 May; 105(5):568-70. PubMed ID: 3132992
[TBL] [Abstract][Full Text] [Related]
19. Uptake of native and deglycosylated ricin A-chain immunotoxins by mouse liver parenchymal and non-parenchymal cells in vitro and in vivo.
Blakey DC; Skilleter DN; Price RJ; Thorpe PE
Biochim Biophys Acta; 1988 Feb; 968(2):172-8. PubMed ID: 3257705
[TBL] [Abstract][Full Text] [Related]
20. Restoration of interferon alpha potentiation of a recombinant ricin A chain immunotoxin following cytoreduction of xenografts of advanced ovarian tumors.
Pearson JW; Fogler WE; Volker K; Riggs CW; Gruys E; Groves ES; Wiltrout RH; Longo DL
J Natl Cancer Inst; 1993 Jun; 85(11):907-12. PubMed ID: 8492319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
